Home >> Signaling Pathways >> Tyrosine Kinase >> Bcr-Abl


Bcl-Abl is a constitutively activated chimeric tyrosine kinase which is the genetic abnormality expressed in patient with CML (chronic myeloid leukemia).

  1. Cat.No. Product Name Information
  2. GC12172 1-Naphthyl PP1 Src family kinases inhibitor
  3. GC15579 Adaphostin P210bcr/abl tyrosine kinase inhibitor
  4. GC11737 AG957 a tyrphostin that targets transforming Bcr-Abl fusion proteins
  5. GC32703 Asciminib (ABL001)
  6. GC10914 AST 487 RET kinase inhibitor
  7. GC10638 AT9283 Aurora kinase/JAK inhibitor
  8. GC35462 Bafetinib
  9. GC17449 Bafetinib (INNO-406) Bcr-Abl/Lyn tyrosine kinase inhibitor
  10. GC33343 BCR-ABL-IN-1
  11. GC33368 BCR-ABL-IN-2
  12. GC13343 Bosutinib (SKI-606) A potent inhibitor of Src and Abl kinases
  13. GC40080 Bosutinib-d8 Bosutinib-d8 is intended for use as an internal standard for the quantification of bosutinib by GC- or LC-MS.
  14. GC17294 CHMFL-ABL-053 BCR-ABL inhibitor
  15. GC33351 CZC-8004 (CZC-00008004)
  16. GC15568 Dasatinib (BMS-354825) Src and BCR-Abl inhibitor
  17. GC35812 Dasatinib hydrochloride A potent and dual AblWT/Src inhibitor
  18. GC14007 DCC-2036 (Rebastinib) Bcr-Abl inhibitor
  19. GC35897 DPH A potent cell permeable c-Abl activator
  20. GC32867 Flumatinib (HHGV678)
  21. GC13914 Flumatinib mesylate PDGRFβ inhibitor

Items 1 to 20 of 42 total

per page
  1. 1
  2. 2
  3. 3

Set Descending Direction